Biopharma firms are in-licensing candidates later according to an industry expert, who says the trend is impacting the contract development and manufacturing sector.

In-licensing—the practice of paying for rights to develop and commercialize a product discovered by another company—is a widely used strategy in the biopharmaceutical industry.

According to a recent report in Nature, the top 10 drug licensing deals in the first three quarters of 2019 were worth $34 billion (€31 billion), an increase of 10 percent from the $31 billion in the corresponding period in 2018.

Some of the notable deals include:

Gilead’s (NASDAQ: GILD) $5 billion Read more »